secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0000950170-24-122296
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector reports Q3 net loss $42.2M ($0.43/share); cash $457.2M funds through 2026
--------------------------------------------------------------------------------

- Cash, cash equivalents, investments $457.2M as of Sep 30, 2024, sufficient to fund operations through 2026.
- Q3 2024 net loss $42.2M ($0.43 per share) vs $44.5M ($0.53) in Q3 2023; collaboration revenue $15.3M, up from $9.1M.
- R&D expenses $48.0M driven by AL101 Phase 2 start; G&A $15.8M includes impairment from lab transition.
- FY 2024 guidance: collaboration rev $60-70M, R&D $210-220M, G&A $60-70M.
- INVOKE-2 (AL002) Phase 2 data due in 2024; INFRONT-3 (latozinemab) top-line late 2025/early 2026; PROGRESS-AD >1/3 enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024122296/0000950170-24-122296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017024122296/alec-20241106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-122296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer